CDX2 and neoplasm: In microsatellite stable UICC Stage II/III CRCs, CDX2-low/absent tumours were associated with a significantly shorter DSS/DFS but not OS (n = 525; OS: P > 0.05; DSS: CDX2-high 160.7 months vs CDX2-low/absent 108.8 months, P = 0.05; DFS: CDX2-high 154.4 months vs CDX2-low/absent 96.8 months, P = 0.009), while in microsatellite-instable UICC Stage II/III CRCs, CDX2 expression had no impact on any survival parameter (OS/DSS/DFS, P > 0.05).